Jenchen Yang
Cardiovascular Disease · Diamond Bar, CANPI 1912084534
Payments from drug & device makers
Across 380 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- Amgen$1K
- Sanofi-aventis U.S. LLC$1K
- United Therapeutics Corporation$675
- Merck$655
- Esperion Therapeutics, Inc.$384
- plus $2K from 22 others
What the payments were for
- Consulting fees$2,02520%
- Travel & lodging$1471%
- Food & beverage$7,80278%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 77 | $3,924 |
| Amgen | 81 | $1,141 |
| Sanofi-aventis U.S. LLC | 46 | $1,033 |
| United Therapeutics Corporation | 27 | $675 |
| Merck | 26 | $655 |
| Esperion Therapeutics, Inc. | 20 | $384 |
| Boehringer Ingelheim | 13 | $280 |
| Regeneron Healthcare Solutions, Inc. | 14 | $272 |
| Kowa Pharmaceuticals America, Inc. | 24 | $200 |
| Philips North America LLC | 3 | $187 |
| Amarin Pharma, Inc. | 8 | $179 |
| AstraZeneca | 8 | $174 |
| Alnylam Pharmaceuticals Inc. | 2 | $146 |
| Novo Nordisk | 7 | $131 |
| Abbott | 1 | $125 |
| Johnson & Johnson | 5 | $119 |
| AbbVie(2 entities) | 3 | $59 |
| Lilly USA, LLC | 2 | $58 |
| Pfizer | 2 | $55 |
| Bayer | 2 | $51 |
| Edwards Lifesciences | 1 | $33 |
| Boston Scientific | 1 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Liquidia Technologies, Inc. | 1 | $22 |
| GSK | 1 | $20 |
| Gilead | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,037 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orenitram ErTreprostinil Diolamine | 180 | $985,763 |
| Repatha SureclickEvolocumab | 421 | $431,247 |
| Sildenafil Citrate | 120 | $297,123 |
| Ambrisentan | 97 | $252,104 |
| MultaqDronedarone Hcl | 144 | $196,369 |
| Praluent PenAlirocumab | 233 | $193,292 |
| EliquisApixaban | 163 | $182,244 |
| Tadalafil | 65 | $126,183 |
| FarxigaDapagliflozin Propanediol | 104 | $115,913 |
| JardianceEmpagliflozin | 84 | $113,290 |
| XareltoRivaroxaban | 74 | $110,090 |
| TrulicityDulaglutide | 43 | $95,207 |
| EntrestoSacubitril/Valsartan | 58 | $84,971 |
| OzempicSemaglutide | 51 | $57,303 |
| BrilintaTicagrelor | 46 | $37,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCMultaq | $1,033 | $196,369144 claims |
| PfizerEliquis | $55 | $182,244163 claims |
| AstraZenecaFarxiga, Brilinta | $174 | $152,946150 claims |
| Boehringer IngelheimJardiance | $280 | $113,29084 claims |
| Johnson & JohnsonXarelto | $119 | $110,09074 claims |
| Lilly USA, LLCTrulicity | $58 | $95,20743 claims |
| NovartisEntresto | $3,924 | $84,97158 claims |
| Novo NordiskOzempic | $131 | $57,30351 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $200 | $22,26828 claims |
| MerckJanuvia | $655 | $15,22821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Diamond Bar
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.